Andera Partners Leads $20 Million Investment in Rivermark Medical

On May 13, 2026, Andera Partners announced it led a $20 million Series D financing for Rivermark Medical, a company specializing in urology medical devices. This investment aims to support the pivotal clinical trial, RAPID III, secure regulatory approval in the U.S., and prepare for the commercial launch of Rivermark's FloStent™ System.

The FloStent™ is designed as a non-surgical, reversible therapy for benign prostatic hyperplasia (BPH), offering a simple, tissue-preserving treatment option. It's delivered in outpatient settings and can be adjusted post-implantation. Previous trials showed positive outcomes with rapid recovery and sustained effects over 24 months, making it a promising BPH solution.

Joining the financing round, Aneta Sottil from Andera Partners commended FloStent's innovative approach and joined Rivermark's Board of Directors to assist in achieving FDA approval and market adoption.